“Change-Management is a team effort – let’s get started”

Dr. Matthias Krings Senior Partner

“At Catenion, I can put my scientific background in cell therapy and regenerative medicine to practical use and help bring innovative therapies to the market.“

Dr. Pascal Joly Manager

“Sitting at the boundary between science and business is an incredibly rewarding experience”

“China’s policy makers are making a concerted long-term effort to build a competitive biomedical innovation system – but R&D-based value creation
is only just beginning.”

Christian Elze Senior Partner

“Helping clients around the globe to unleash the power of immune system in the fight against a plethora of diseases is a very rewarding career path for a trained immunologist.”

Dr. Jelena Nedjic Associate

“From bench to bedside and beyond: Translating inspiring science into innovative business strategies is a fascinating journey”

“Is biopharma ready to embrace the new biology?”

Dr. Markus Thunecke Senior Partner

„How can patients and the legislature steer the biopharmaceutical industry towards sustainable innovation?“

Dr. Anela Vukoja Associate

“I help R&D teams deliver on the promise of gene therapy”

“Weaving the science and commercial together to sew targeted solutions for our clients: that is my goal”

Min Ji Kim Research Analyst

“Uncovering the real value of technologies for our clients by seeing through the smoke and mirrors of the industry is just one of the fascinating aspects of working at Catenion”

‘Enhance decision making through a data-driven approach: challenging assumptions and exploring new ideas – this is our passion’

“Using my scientific expertise to identify game-changing technology and solve strategic RnD challenges combines my passion with real outcomes”

Spotlight

In Vivo Biopharma RD Productivity-Growth 2018

In 2017, R&D productivity of the top-30 pharmaceutical companies had decreased for the first time since 2014, according to ….
Download

Financier – M&A in biopharma – why bigger is not better

Numerous studies by academics and consultants demonstrate that M&A, on average, destroys value. A recent study performed on the Russe II 3000 index from 2001 to 2013 shows that most M&A is dilutive to earnings growth over an extended period post-merger. …
Download this article

Meet Us

March 1, 2019

“Maximizing Value from Strategic Partnering in Clinical Development” Greenberg Traurig – Tokyo

March 2, 2019

New York Academy of Sciences – The Future of Biopharmaceutical Innovation – New York

more
April 4, 2019

“Can Israel build a sustainable biopharma industry?” Tel Aviv University